Open AccessNeoadjuvant ceritinib treatment in ALK ‐rearranged locally advanced adenosquamous carcinoma: A case report
Author(s) -
Mai Shixiong,
Wang Yue,
Wang Xuemei,
Yang Wei,
Gao Haicheng,
Xu Zhenan,
Xu Lei,
Xu Li,
Ou Qiuxiang,
Chen Hanlin,
Wang Zhenxing
Publication year - 2022
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14558
Subject(s) - medicine , ceritinib , alk inhibitor , adenosquamous carcinoma , neoadjuvant therapy , oncology , adenocarcinoma , anaplastic lymphoma kinase , lymph node , pathology , lung cancer , cancer , breast cancer , malignant pleural effusion
Abstract Here, we first report a case of neoadjuvant ceritinib for locally advanced lung adenosquamous carcinoma. In this study, a locally advanced adenosquamous carcinoma (ASC) patient with EML4‐ALK fusion who achieved a partial response with neoadjuvant ceritinib treatment after a cycle of neoadjuvant chemotherapy did not show significant efficacy. A complete surgical resection was performed with mild adhesions and a small amount of bleeding intraoperatively. The EML4‐ALK fusion was detected by targeted next‐generation sequencing (NGS) in both pretreatment biopsy and the postoperative tissue specimens with a dramatic decrease in the allele frequency (26.2% [pre]–2.3% [post]). Pathological examination of the postoperative specimens indicated a diagnosis of ASC but the proportions of adenocarcinoma and squamous cell carcinoma cells in the primary lung tumor and metastatic lymph node site were different, suggesting the various responses to ceritinib. Thus, with the case presented here, we provide the clinical evidence for ALK ‐positive locally advanced ASC patients benefiting from neoadjuvant ceritinib treatment with a tolerable safety profile, whereas further cohort studies of the efficacy and safety of neoadjuvant ceritinib in such patients are needed.